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Of the seven pilot schemes reviewed, the small-scale 
health insurance schemes show limited success owing 
to smaller pool and limited managerial capabilities. The 
large schemes offer avenues for mainstreaming but 
pose issues of governance as well as marketing among 
PLHIVs. The findings of the research identify a specific
set of issues and challenges for sustainability and 
replication from three perspectives viz. a) market, b) cost 
recovery and sustainability and c) equitable coverage.
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Introduction
India’s health situation, although improved over time, 
remains a major cause of concern compared to other 
industrialising countries. Owing to a demographic trans-
ition, India has witnessed an increasing proportion of young 
population over the last few decades and this scenario 
is likely to continue for another two decades or so. [1] 
This is particularly important, as the young population is 
vulnerable to Sexually Transmitted Infections (STI), including 
Human Immunodeficiency Virus (HIV). India continues to 
Abstract
Millions of Indians fall into poverty because of the 
private high Out of Pocket pattern of health financing, 
due to the absence of insurance coverage. Conditions 
like HIV and AIDS also influence poverty due to a life-
long treatment requirement. Access to insurance 
coverage (commercial or voluntary) has been denied to 
People Living with HIV (PLHIV) through various clauses. 
However lately, there have been certain experiments 
on inclusion of HIV into new or existing schemes. 
This paper provides a systematic review of coverage, 
managerial and financial systems of selected cases of 
HIV insurance pilots in India with an objective to explore 
its sustainability and ability to be replicated.
A cross-sectional descriptive analysis of existing 
literature and in-depth case studies of relevant health 
insurance schemes were used for the review. Data was 
compiled using qualitative data collection tools such 
as in-depth interviews with officials. The schemes 
were analysed using two frameworks viz. managerial 
ability and coverage ability. The managerial ability was 
analysed through a Strength-Weakness-Opportunity-
Threat (SWOT)  analysis. The coverage ability was anal-
ysed through three dimensions viz. a) breadth b) depth 
and c) height. In India, there are two types of insurance 
policies vis-à-vis HIV coverage. These were categorised 
as HIV-specific and HIV-sensitive policies.
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have a reasonably high burden of HIV infection and a related 
condition called Acquired Immune Deficient Syndrome 
(AIDS). [2] India does not have a generalised epidemic, and 
in comparison with many southern and eastern sub-Saharan 
African countries, it has a lower HIV prevalence as well. 
According to latest available estimates, India had an adult 
HIV prevalence of 0.26% or around 2.11 million People Living 
with HIV (PLHIV) in 2015. [2] In relative terms, the burden 
of HIV in India may not seem very high, but in an absolute 
sense, the burden of more than two million individuals 
is significant. HIV has spread widely across various states 
and across various sections of the population in India, and 
has been recognised as the most important public health 
issue in recent times. [3-5] The decreasing mortality and 
yet continuing incidence of HIV infection indicates that an 
increasing number of people are going to need treatment 
and care over time. [6-8]
There is no cure for HIV infection. However, there is a 
therapy called anti-retroviral therapy (ART) through which 
the infection can be managed. The ART includes provision 
of drugs and medicines, laboratory examinations including 
measurement of performance of immune system in terms 
of CD4 count – a lab test that measures the number of 
CD4 T lymphocytes (CD4 cells) – and medical as well as 
psychological consultation. Since its commencement in 
2004, India’s free ART programme has grown steadily. By 
2014, it had expanded to cover more than 850,000 eligible 
patients through more than 400 ART centres across the 
country. [2] Despite the availability of free ART, poor families 
need to spend Out-of-Pocket (OOP) to meet health expenses 
arising out of treatment of certain opportunistic infections, 
including hospitalisation. There has been evidence of PLHIV
facing financial burden while seeking treatment therapy 
under the government programme. [9-14]
The linkages between high spending on health and its effect 
on poverty – in terms of pushing many people below the 
poverty line, and affecting the living status of households 
who are already poor – are well established. [15-18] While 
on one hand, the catastrophic expenses arising out of 
hospitalisation in the absence of health insurance coverage 
have also been well documented, [19-21] people living with 
chronic conditions, whose spending is mostly outpatient 
in nature, are also vulnerable to the effect of rising OOP 
expenditure. [22] Although chronic conditions are largely 
associated with non-communicable diseases, the financial 
implications of communicable diseases like HIV and AIDS 
also influence poverty in a similar manner. While the impact 
of poverty on increased vulnerability to HIV infection has 
been debated, [23-25] the household level socio-economic 
impact of the infection has been well documented. [14, 26-28]
The OOP - due to lack of health coverage - is experienced by 
everyone, but the access to commercial or voluntary health 
coverage by purchasing health insurance at a premium has 
been denied to PLHIV in India through various clauses of 
different insurance policies.
These exclusions are of two types, a) pre-existing conditions, 
and b) permanent exclusions. The pre-existing conditions 
clause refers to those conditions that existed at the time of 
enrolment. The permanent exclusion clause is for certain 
conditions that are excluded ‘forever’ from the list of benefits, 
irrespective of the time of their occurrence.
STIs including HIV are one such ‘permanent exclusion’. 
While the exact wording for such exclusions can vary 
across policies, one of the mainstream health insurance 
policy reads as follows: ‘Sexually transmitted diseases, any 
condition directly or indirectly caused due to or associated 
with Human T- Cell Lymphotropic Virus Type III (HTLB-III) 
or Lymphotropathy Associated Virus (LAV) or the Mutants 
Derivative or variation Deficiency Syndrome or any 
syndrome or condition of a similar kind commonly referred 
to as AIDS’. Certain preexisting chronic diseases like diabetes 
are covered in selected health insurance policies either 
after a waiting period or with additional premiums. Such 
coverage is almost nonexistent for HIV-related conditions.
The situation of health insurance for HIV in India has evolved 
over time. The discourse around insurance for HIV changed 
in the 2000s because of a) successful scale up of free ART 
programme, b) stabilisation of incidence of HIV cases, and c) 
emerging global debate on universal health coverage and 
the rollout of state and nation-wide government funded 
health insurance schemes.
HIV coverage in India started in schemes that provided 
employment-based coverage. The social health protection 
schemes like the Employee State Insurance Scheme, Central
Government Health Scheme and organisations like the 
Railways and Defence, were providing all HIV care, including 
free access to ART. [29] However, such coverage was by 
default rather than design. With very limited coverage and in 
the absence of a free ART programme till 2004, the advocacy 
for mainstreamed financial coverage for HIV started with 
focus on covering ART for those outside the net of such 
schemes. During the 1990s and the first half of 2000s, along 
with advocacy for coverage by activists and researchers, 
there were also discussions within the insurance industry 
to start learning about the epidemic so as to prepare for 
product development. [30]
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Despite the changing nature of favourable discourse about 
insurance for HIV, there remained a denial of coverage by 
the mainstream commercial insurance schemes. [31] As a 
result, a number of pilots were initiated to demonstrate the 
possibility of such coverage.
These included a) Freedom Foundation Health Insurance 
Policy (FF-HIP), b) Karuna Trust health insurance scheme, 
c) Aarogyasri scheme, d) Yeshasvini Co-operative Farmers 
Health Care Scheme, e) Mukhya Mantri Jeevan Raksha 
Kosh Yojana (MMJRK), f ) Rashtriya Swasthya Bima Yojana, 
(RSBY), and g) Star Health Insurance Netplus health insur-
ance scheme.
Of these seven schemes, the first two schemes were 
pilot projects initiated by United Nations Development 
Programme (UNDP). The next were three (c-e) were state-
level schemes from Andhra Pradesh, Karnataka, and 
Rajasthan states, respectively. The RSBY is a Pan-Indian 
health insurance scheme for low-income sections of the 
society. Lastly, the Star Netplus health insurance scheme 
was exclusively offered to a group of PLHIV in partnership 
with a Non-Governmental Organisation (NGO) called 
Population Service International Connect.
This paper provides a comparative analysis of the above-
mentioned seven insurance schemes from the perspective 
of their coverage as well as management potential.
Methods
This is original research that involved cross-sectional 
descriptive analysis of existing literature and in-depth case 
studies of relevant health insurance schemes. The data 
sources were a review of secondary data, observation, 
and interviews with managers of the schemes. Two major 
objectives were a) to review the managerial and financial 
systems of selected cases of HIV insurance schemes in 
India, and b) to explore their efficacy, sustainability and 
ability to be replicated. An in-depth review was carried 
out based on case studies of each scheme, comparing 
their unique features and using an analytical framework. 
The schemes were analysed from two broad perspectives. 
a) managerial ability, and b) coverage ability. The manag-
erial ability was analysed through a SWOT (Strength-
Weakness-Opportunity-Threat) tool. The internal environ-
ment of the schemes was analysed to understand their 
strengths and weaknesses and the analysis of the external 
environment yielded opportunities and threats to these 
kinds of schemes. The coverage ability was analysed 
through the three dimensions of Universal Health Coverage 
(UHC), a) breadth i.e. the magnitude of the population that 
is covered, b) depth which includes the extent or scope of 
various health services that are covered, and c) height in 
terms of the level of financial protection or sum insured 
amount offered in the coverage. A framework was developed 
to analyse the coverage ability of various schemes.
The framework involved a set of sub-components across the 
three UHC components. These sub-components, used as 
variables for analysis, were given weights that were applied 
to these variables/scores to quantify the performance of 
schemes across the three dimensions. This ultimately helped 
arrived at a UHC index. The details of variables and their 
scores are described in Table 1. Assessment of managerial 
and coverage ability through a SWOT and UHC analysis is 
original research, and adds to existing knowledge.
Table 1: Framework for analysis and weighted scores of components
UHC COMPONeNT  SUB-COMPONeNT OF UHC  SCORe
Depth of coverage In terms of scope of services Outpatient services  1
 Inpatient services  1
 Operative procedures  2
 STI treatment  1
 OI treatment  1
 ART  2
 Maternity benefits  1
 Choice of providers  1
Height of coverage In terms of scope of financial protection Less than Rs. 100,000 per annum  3
 More than Rs. 100,000 per annum  6
 Unlimited  9
Breadth of coverage In terms of scope of population coverage Stage specific PLHIV  3
 BPL PLHIV  6
 All PLHIV  9
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Analysis
A brief description of seven cases is provided below before 
analysing them from a coverage and managerial ability 
perspective.
Freedom Foundation Health Insurance Policy
Freedom Foundation (FF) initiated a two-year pilot project 
in 2006, to explore the feasibility of offering an insurance 
scheme for PLHIV to cover their medical expenses including 
cost of ART, Opportunistic Infections (OI) management, 
and periodic testing including CD4 counts, on a graduated 
cost recovery model. All above-mentioned services were 
provided to all ART-eligible individuals visiting FF, Bangalore 
by a team of experienced healthcare providers. A Health 
Insurance Policy (HIP) was offered as a joint venture with the 
UNDP, in which the foundation acted both as insurer and 
service provider.
Under the scheme, the insured clients were to receive the 
coverage benefits – up to a total sum insured of Rs. 13620 
(US$ 227) per year at a payment of stipulated premium, 
which were on a sliding scale based on economic categories. 
Only sixty-nine people were enrolled as against the target of 
158 individuals who were ART-eligible because of their CD4 
counts. Overall, against the total premium collection of Rs. 
301,002, (US$ 5017), the corresponding claim amount was 
Rs. 433,257. (US$ 7221). Despite having a good adherence 
and treatment follow-up, the scheme was withdrawn at 19 
months, despite the original plan of 24 months. The main 
reason for the withdrawal was the financial nonviability of 
the scheme, which is attributed to an inability to recruit 
enough clients to the scheme. The foreclosure report 
indicated three major reasons for this: a) lack of awareness 
about health insurance, b) financial constraints, and c) 
availability of the free government ART programme. [32]
Karuna Trust experiment
Karuna Trust has offered a health insurance scheme in 
association with UNDP and the National Insurance Company 
during 2002-2005. This scheme was targeted towards the
poor, and offered free hospitalisation coverage at the stip-
ulated government facilities.
The annual premium of Rs. 30 (US$ 0.5) was subsidised for 
various sections of society. The scheme had a component 
of no-exclusion, and thus, was one of the first Community 
Health Insurance schemes to have covered ‘all illnesses’ 
including pre-existing conditions.
In this context, by virtue of no-exclusion, HIV-related 
illnesses were also covered under the policy. However, 
with very limited coverage amount, costly ART treatments 
or monitoring tests were not covered. In 2006, UNDP and 
Karuna Trust extended their partnership to mainstream 
HIV intervention in primary care, and covered ‘some 
investigations as well as treatment of OIs’. [33] Under the 
scheme, HIV was being mainstreamed in primary health 
care and included a novel concept of offering PHC Voluntary 
Counselling and Testing Centres. The extended scheme also 
went on to cover more than 49,000 people by July 2007. The 
scheme also reimbursed Rs. 2,99,400 (US$ 4990) towards 
claims. [34] The UNDP partnership with Karuna trust ended 
in 2007. There is lack of documentation or evaluation of this 
scheme.
Star Netplus Health Insurance
A private health insurance company – Star Health and Allied 
Insurance Co. Ltd – has offered an insurance product aimed 
at PLHIV since July 2007. The group policy offered coverage 
to all HIV positive individuals who were yet to reach the 
AIDS stage. The ‘Star HIV Care Policy’ offered critical illness 
coverage, in which the insured person received limited 
monetary assistance against the onset of a pre-decided 
event. [35] From 2008, a partnership between PSI Connect 
and Star Health initiated a pilot project through which a 
composite policy with both lump sum payments as well 
as hospitalisation benefits were developed as a part of 
the single coverage. On one hand, while the insured were 
given a choice of providers, the project also made efforts 
to sensitise more than 1000 hospitals.
However, It offered enrolment only to a group of around 
200 PLHIV, a condition that left individual aspirants out of 
the coverage. As a promotion, the scheme had a subsidy 
component wherein 50 per cent premium for the base 
product was provided through USAID funds under the 
Connect project. From a modest beginning of an annual 
enrolment of 256 PLHIV in 2008, the scheme went on to 
cover more than 7000 PLHIV in 2010. It was estimated that 
the aggregate claim rate under the scheme was 11 per cent 
and average claim of Rs. 4,954 (US$ 83). [35] Although the 
partnership between Star Health and Project Connect ended 
in 2011, this scheme is still functional with revised coverage.
State Sponsored Large Scale Schemes
As discussed earlier, several government-sponsored schemes 
operate in India. Most of these schemes contribute to the 
larger goal of universal coverage. Among these, a major 
state-level health insurance initiative is the Rajiv Aarogyasri 
CHI Scheme (Aarogyasri) of the Andhra Pradesh government. 
Functional since 2007, the scheme caters for around 65.4 
million poor people across the state. The scheme is free to 
beneficiaries as the state government pays the premium to 
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the designated insurance company. [36] Aarogyasri had an 
inclusion clause in the scheme that ensured that ‘treatment 
for all the identified diseases, including HIV and Hepatitis-B 
related conditions’ are covered by design. [37] The scheme 
offers coverage of tertiary care of 938 predefined treatment 
and follow-up packages.
Another ambitious government-sponsored scheme, RSBY 
was launched in 2008. The scheme is being offered in 25 
states in partnership with insurance companies to provide 
financial coverage from hospitalisation expenses up to 
Rs. 30,000 (US$ 500) per family per year, who has opted 
to become a member by paying Rs. 30 (US$ 0.5) for the 
membership.
The entire premium is paid jointly by the central and state 
governments. In RSBY, HIV was excluded in during the first 
year. Later on, from the second year onwards, it was removed
from the list of conditions that are permanently excluded. 
[38]
Both these schemes are meant only for the population 
owning a Below Poverty Line (BPL) card – an identity 
proof issued by government to poorer sections of society. 
This means that individuals who are HIV positive but 
do not possess a BPL card are not covered. To the best of 
author’s knowledge, currently, there are no estimates on 
the proportion of PLHIV who are also BPL cardholders. This 
makes the coverage of HIV positive people in government 
sponsored schemes more debatable.
A similar large-scale scheme is Yeshasvini Cooperative 
Farmers Health Care Scheme in Karnataka. The scheme 
started in 2003 and offers coverage to more than three 
million beneficiaries against specified surgeries and 
procedures. It is open only to registered members of the 
specified cooperatives in the state. Started with a premium 
of Rs. 60 (Us$1) per year per person, the scheme as of 2011-
12 operates at an annual premium of Rs.160 (US$ 3) per 
member. This self-funded scheme does not have insurance 
coverage from any insurance company; it is operated by 
the Yeshasvini Trust, and a TPA called ‘Medi Assist India TPA 
Pvt. Ltd.’ is the risk-bearer entity. It covers free consultations, 
diagnostics at discounted rates, and over 1700 types of 
operations. Although not designed in the original plan, the 
scheme currently does not exclude HIV positive individuals. 
Since 2008, Yeshasvini coverage has been extended to all 
pregnant women who are found to be HIV positive during 
their antenatal check-ups.1
Even before the GoI free ART programme, Rajasthan 
provided partial funding for ART for specified poor patients 
through the Chief Minister’s Relief Fund in Rajasthan. 
[39] Even after penetration of GoI’s free ART programme, 
Rajasthan continued to offer HIV coverage through the 
MMJRK. Launched in January 2009 for the BPL families, 
the scheme aims to provide free secondary and tertiary 
health services. The coverage includes all kinds of inpatient 
as well outpatient services, conveyance, largely through 
government hospitals and selected thirty-two private 
hospitals. Although not included as a fundamental design 
of the scheme, in December 2009 PLHIV were accorded 
BPL status, and thus made beneficiaries of the scheme. 
[40] According to an official from the Rajasthan State AIDS 
Control Society, more than 12,000 patients have benefited 
from the scheme during April-December. [41] Details of 
these seven schemes are summed-up in Table 2.
The seven schemes (cases) can be broadly classified into two 
categories, HIV-sensitive policies and HIV-specific policies. 
The HIV-sensitive policies include schemes that already exist 
but have been modified to include PLHIV and also schemes 
that have been developed to proactively include PLHIV, 
along with other communities. The HIV-specific policies are
insurance schemes that are exclusively developed for and 
cater to PLHIV. Of the seven schemes described above, FF-
HIP and Star Netplus schemes are examples of HIV-specific 
policies, and the remaining five are categorised as HIV-
sensitive policies that cater for other vulnerable groups 
as well. The two groups of schemes were analysed from 
managerial ability and coverage ability perspectives. The 
managerial ability was analysed through a SWOT analysis. 
The coverage ability was analysed through the lens of three
dimensions of UHC, a) breadth, b) depth and c) height, as 
discussed earlier.
Managerial ability - SWOT Analysis
The SWOT analysis of HIV-specific policy is summarised in 
Figure 1. The various strengths of the HIV-specific schemes 
include a) motivation of the promoters, b) customised prod-
ucts, c) choice of providers with technical competency to 
treat HIV related complications, and d) community action/
involvement. The biggest strength of HIV-specific schemes is 
the high level of motivation by the promoters of the schemes. 
The efforts of Freedom Foundation and Star Health resulted 
in the evolution of first-of-its kind of schemes that provided 
tailor-made features. Schemes like FF-HIP featured in-house 
clinical care by a medical team that has been offering care 
over many years. On the other hand, Star can ensure access to 
quality clinical care with a Netplus scheme with a free choice 
1 See circular no. NRHM/MCH/61/08-09, at http://karhfw.gov.in/
nrhm2/7.pdf, [accessed August 3, 2011].
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of providers. This enabled the insured to access providers 
who were expert in treating HIV-related illnesses. Lastly, 
being schemes which were run either by a care and support 
organisation or through a network of positive people, they 
ensured community linkages and actions through group 
formation and community involvement.
The weaknesses of such schemes include a) small pool of 
beneficiaries, b) no or little risk pooling, c) limited financial 
protection, d) high premium-low coverage mix, and e) 
low sustainability. HIV-specific schemes, being disease-
specific schemes, offer a limited scope of pooling in terms 
of magnitude of members and risks. With limited pooling 
and mandates to cover expensive treatment, these schemes 
rely on a) higher premiums b) selection of coverage, and c) 
subsidies. Both FF-HIP and Star Netplus schemes offered 
limited financial protection (up to Rs. 30000 or Us$ 500) to 
selected individuals (eligible in terms of CD4 counts), and 
had to rely on subsidies (UNDP and USAID, respectively) 
to make the premium affordable. This resulted in poor 
sustainability and limited commercial viability of such 
schemes like FF-HIP, especially in absence of donor funds.
Table 2: Comparison of schemes covering PLHIV in India ( Adapted from (Trivedi and Gupta 2012)
SchemeS
ParameterS DetailS of
 Karuna freeDom Star rSBY aarogYaSri YeShaSvini mmJrKthe Scheme
 truSt founDation netPluS 
Who are covered All PLHIV  Ö
BPL PLHIV  Ö  Ö  Ö  Ö
Stage specific PLHIV Ö  Ö
What benefits are Outpatient services  Ö  Ö  Ö  Ö  Ö
are covered
Inpatient services  Ö  Ö  Ö  Ö  Ö
Operative procedures  Ö  Ö  Ö  Ö  Ö  Ö
STI treatment  Ö  Ö  Ö  Ö  Ö
OI treatment  Ö  Ö  Ö  Ö  Ö
ART  Ö
Maternity benefits  Ö  Ö  Ö
Choice of providers  Ö  Ö  Ö  Ö
What cost is Sum insured amount Rs.  Rs. Rs.  Rs. Rs. Rs. Unlimited
covered (Rs.) 30,000  13620  30,000 30,000 200,000 200,000
Figure 1: SWOT framework for HIV-specific policies 
STReNGTH  WeAKNeSS
Motivation of the promoters Small pool of beneficiaries
Customised products No or little risk pooling
Technical competency of the providers Low sustainability
Community action/involvement High premium-Low coverage mix
Limited financial protection
OPPORTUNITY  THReATS
Depleted funding from development partners
Cream skimming
Knowledge generation (Evidence) 
Advocacy – Adoption by insurance cos. 
and funding agencies 
Community mobilisation Partnership issues
Poor interest among insurer
Poor interest among providers
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The opportunities of HIV-specific schemes are three-fold, 
viz. a) knowledge generation, b) advocacy for product 
innovation and c) community mobilisation. Looking at the 
external factors, the biggest contribution these schemes 
provided was new evidence on the experience of covering 
HIV-related expenses through a health insurance mechanism. 
These schemes provided data on illness profiles, treatment 
seeking and health expenditure. Such data can feed into the 
actuarial calculation and provide opportunities for product
development in the long run. Similarly, these schemes 
provided avenues of renewed and sustained advocacy for 
coverage for HIV by being pioneers in the field. The data and
advocacy can influence policymakers to incorporate health 
insurance in the realm of care and support policies. Lastly, 
the evidence of performance of schemes, in terms of claims
rate and average claim amount, can also generate interest 
among insurance companies as well as funding agencies 
to support mainstreaming of HIV into commercial health 
insurance.
The threats to such schemes include a) depleted funding 
from development partners, b) cream skimming among 
insurers, and c) partnership issues with insurer and providers. 
The reliance on outside funding to support the premium 
remains the biggest threat for HIV-specific schemes; 
reduced funding can seriously harm the very existence of 
such schemes.
Another threat remains with cream skimming; insurer and 
provider tend to choose relatively low-risk clients leaving 
the end-stage PLHIV out of the pool. This means there may 
be a tendency to choose relatively healthier HIV cases (with 
higher CD4 count) while not insuring and treating the AIDS 
cases (with lower CD4 count). Finally, in the absence of a 
policy mandate, important stakeholders, i.e. risk-bearers like 
insurance companies and healthcare providers, can opt-out 
of partnerships. This can affect the performance as well as 
sustainability of the schemes.
A similar SWOT analysis on HIV-sensitive policies, i.e. the 
remaining five schemes that covered PLHIV along with 
other vulnerable populations, is outlined in Figure 2. The 
most positive outlook of HIV-sensitive schemes is their 
mainstreaming nature, which does not discriminate based 
on a person’s HIV status. These schemes treat HIV like any 
other conditions and provide a case for an ideal way of 
mainstreaming HIV into existing coverage options. Second, 
they offer a wider pooling, both in terms of number of 
members as well as their risks. With the exception of Karuna 
Trust, all other HIV-sensitive schemes are population-wide 
schemes spread across the states, and ensure coverage to 
entire family irrespective of their risks. The large pool, as well 
as government sponsorship, reduced the premium to very 
low or nil in the majority of cases, which makes the schemes 
affordable to the entitled. The component of government 
ownership in such schemes makes them sustainable, at least 
in short to medium term. Lastly, unlike HIV-specific policies, 
HIVsensitive policies cover HIV unrelated conditions as well, 
and thus offer diversified and holistic coverage.
While being all-inclusive is a strength of HIV-sensitive 
policies in terms of being nondiscriminatory, the same 
characteristic also result in one of the weaknesses. Unlike 
HIV-specific schemes, HIV-sensitive schemes are not 
tailor-made and thus, may not cover, for example, certain 
expensive treatments. Another weakness of such schemes 
is the fact that PLHIV not owning a BPL card may not get 
covered in most schemes. Since the enrolment is based on 
owning a BPL card, poor PLHIV, in the absence of such card, 
may be excluded.
Figure 2: SWOT framework for HIV-sensitive policies
 STReNGTH  WeAKNeSS
 Mainstreaming
 Large pool- greater pooling Coverage may not be need-specific
 Sustainability Governance issues
 Affordable premium Eligibility – non-BPL are excluded
 Diversification of coverage Competency of providers
 OPPORTUNITY  THReATS
 UHC 
 Pro-poor Poor marketing among PLHIV
 Linkages with other govt. programmes Change in government insurance policy
 Advocacy for funding for non-BPL PLHIV Change in government care and support policy
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Similarly, these schemes often have governance issues in 
terms of improper implementation at enrolment as well 
as utilisation levels. Finally, at least in the case of Karuna 
Trust and MMJRK scheme of Rajasthan, there is no choice of 
provider and benefits are largely available from public sector 
facilities only. Providers catering to the general population 
may not be oriented towards clinical as well as non-clinical 
needs of PLHIV, behaviours that can affect their healthcare 
utilisation under such schemes.
Looking at the external factors, these schemes provide an 
excellent platform for advocating universal coverage by 
ensuring that specific conditions are not excluded. Being 
insurance schemes for the poor, they also contribute to 
the argument of the poverty alleviation ability of insurance 
schemes, especially for diseases like HIV. HIV-sensitive 
schemes provided learning for linking the community 
to other government-sponsored health as well as social 
security programmes. Lastly, there is an opportunity to 
cover nonpoor PLHIV in such schemes, by awarding them 
conditional BPL status or through inviting private funding 
to subsidise the premium for them. Threats to HIV-specific 
schemes include poor marketing of such benefits to the 
subset of PLHIV In the community; in the environment of 
non-coverage, inadequate awareness of such benefits can 
reduce utilisation of benefits even after enrolment. In the 
event of a change in the stand of government policy of 
insurance or HIV care and support, sustainability and utility 
of these schemes can be jeopardised.
Coverage ability -–UHC analysis
The seven schemes were analysed from the lens of three 
dimensions of UHC, as outlined above. Although all these 
schemes provided coverage for HIV, they perform differently 
in their characteristics in terms of coverage across breadth, 
depth and height. The breadth indicates the level of the 
population that is covered, the depth includes the extent or
scope of various health services that are covered, and 
the height is measured in terms of the level of financial 
protection offered in the coverage. The performance of 
schemes across these dimensions was scored based on the 
framework and index value, as described earlier. Relative 
performance of various schemes across components of UHC 
– in the scale of one to ten – is provided in Table 3. These 
scores were then plotted in a Radar chart using MS-Excel 
for better visualisation of relative performances of schemes. 
These charts are presented as Figure 3-6. HIV-specific and 
HIV-sensitive policies perform equally in terms of depth as 
they cover a variety of diseases, conditions and procedures. 
However, HIV-specific schemes offer relatively lower cover-
age breadth and height and limited financial coverage. 
HIV-sensitive schemes, by their nature of being all-inclusive, 
offer wider scope of coverage across populations and across 
disease conditions. Thus, they have better performance in
breadth and height of coverage. This comparison is illust-
rated in Figure 3 below.
Table 3: Three dimensions of HIV coverage: A comparison across schemes
 ReLATIVe PeRFORMANCe ACROSS 
TYPe OF POLICIeS PILOT SCHeMe COMPONeNTS OF UHC (SCORe OUT OF 10)
  BReADTH  HeIGHT  DePTH
HIV-specific policies  Freedom Foundation  3  3  5
 Star Netplus  3  3  6
HIV-sensitive Policies Karuna Trust  6  3  6 
 RSBY  6  3  8
 Aarogyasri  6  6  4
 Yeshasvini  6  6 5
 MMJRK  9  9  7
Trivedi, M. and I. Gupta (2012). “HIV Insurability in India: Early History and Current Status.” Journal of Health Management 14(4): 435-450.
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Looking at the individual schemes under the HIV-specific 
category, being disease-specific schemes, both FF-HIP 
and Star Netplus scheme have low a breadth of coverage; 
they offer a limited scope of risk pooling as both of them 
cover individuals only in late stage of infection. Star Netplus 
scheme covered relatively healthier PLHIV – and thus has 
relatively better risk pooling – but the FF-HIP lacked risk 
pooling altogether. Additionally, Star Netplus scheme had 
provision for exclusion of advanced cases of AIDS patients. 
This meant that the coverage for insured clients was 
automatically terminated once the lump sum amount at the 
stage of full-blown AIDS, and was not offered renewal of the
hospitalisation coverage. As for the depth, i.e. the range of 
clinical procedures covered for management of HIV, both 
these schemes covered OI treatment, treatment for sexually 
transmitted infections, and inpatient hospitalisation. While 
FF-HIP covered ART and Star Netplus scheme covered 
operative procedures, neither of them covered maternity 
benefits. Both the schemes also offered very limited height 
of coverage i.e. highest amount that will be reimbursed 
under the coverage; while FF-HIP had coverage for around 
Rs. 13,000, (US$ 217); the most common Star Netplus 
package had effective hospitalisation coverage of Rs. 15,000 
(US$ 250) only.
This is low compared with sum-insured of HIV-sensitive 
schemes in the range of Rs. 30,000 – 200,000 (US$ 500-3333). 
Both the schemes also performed poorly on breadth and 
height parameters; while Star Netplus performed slightly 
better in terms of depth of coverage, owing especially to the 
fact that it offered a choice of coverage as well, the FF-HIP 
also performed poorly in this aspect. Across the schemes, 
these two score poorly in terms of universal coverage, 
as can be seen from Figure 4. However, the contribution 
of Star Netplus, in terms of generating first-of-its kind of 
data for actuarial calculations, is significant and generally 
acknowledged.
Figure 3: Three dimension of HIV coverage – a comparison 
across HIV sensitive and HIV specific policies
The individual schemes among the HIV-sensitive schemes 
were divided into two segments for UHC analysis. The 
first segment was schemes with moderate performance 
and included the Karuna Trust, Yesashvini and Aarogyasri 
schemes. The second segment included RSBY and MMJRK, 
which were top performers from the UHC perspective. 
Detailed analysis and description of their performance is 
provided below. In the first segment, all three schemes 
offer moderate breath of coverage as they leave out 
individuals who do not have a BPL card or who are not part 
of cooperative groups.
Karuna Trust scheme has been the frontrunner in offering 
coverage without any exclusions. It offers coverage to BPL 
populations only. Similarly, Aarogyasri as well as Yesashvini 
schemes offer coverage to only those who happen to be 
part of the specified subpopulation.
Yesashvini scheme, although covering HIV positive pregnant 
women, has this limitation of coverage within the specified 
eligibility.
As for the depth of coverage, there are differences and 
Karuna Trust scores higher than the two other schemes. 
While the former covers all clinical procedures, the latter two
offer only critical illness coverage for specified surgeries and 
conditions, and thus, for example, do not cover OI related 
hospitalisation. Among the two state-specific schemes, 
Figure 4: Three dimension of HIV coverage – comparison 
across HIV specific  schemes
BREADTH
DEPTH
HIV specific HIV sensitive
BREADTH
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70 Asia Pacific Journal of Health Management 2017; 12: 1
Yesashvini scores slightly better as it covers maternity 
benefits as a part of the convergence of National Rural 
Health Mission - National AIDS Control Programme initiative.
As for the height of coverage, Karuna Trust scheme performed 
poorly with low sum-insured amount as compared to the 
two other schemes which had sum-insured amount of Rs. 
200,000 (US$ 3333). Figure 5 provides a comparison of these 
three schemes, which performs moderately among the 
seven schemes from the perspective of universal coverage.
The second segment of HIV-sensitive scheme includes two 
top performers among all schemes i.e. RSBY and MMJRK of 
Rajasthan. The common factor in both these schemes was 
the high level of depth of coverage; both the schemes by 
and large covered all outpatient and inpatient services, OI 
treatments, STI treatments and maternity benefits.
RSBY performed slightly better in terms of depth as it offers 
a wider choice of providers within and outside government, 
as compared to its Rajasthan counterpart, where one has 
to rely heavily on government providers. For the other two 
parameters i.e. breadth and height of coverage, MMJRK 
scored way above RSBY. The MMJRK offered great height of
coverage through unlimited amount of financial cover as 
compared to very limited financial coverage of RSBY. A very 
important breadth of coverage related initiative of MMJRK 
is offering PLHIV BPL status to the HIV positive population. 
Thus, while schemes like RSBY, Aarogyasri and Yeshasvini 
do not exclude HIV related conditions, MMJRK goes a step 
further and includes all PLHIV into the net of coverage. These 
characteristics make MMJRK the top performer among the 
seven insurance coverage schemes though relatively very 
high breadth and height of coverage. Figure 6 illustrates this 
comparison.
Figure 5: Three dimension of HIV coverage: comparison 
across selected HIV sensitive schemes
Practice Implications
The World Health Organisation has reiterated the need for 
universal health coverage, which essentially means that 
everyone will have access to health services and will not 
suffer financial hardships paying for them. [42] Various 
countries, including India, have started thinking along 
the lines of UHC as recommended by the WHO. Now, and 
especially in the light of discussions around UHC, the debate 
for mainstreaming HIV in insurance is being nested within 
the discourse on health equity and treating HIV as any other 
disease that impacts the poor and vulnerable to a greater 
extent. While there has been a great deal of debate around 
universal health coverage in India, there is limited discourse 
around the disparities in health insurance system that affect 
the equity and efficiency aspects of coverage in the form of 
excluding certain conditions.
The last decade witnessed quite a few efforts to address 
the issue of covering emerging diseases like HIV and AIDS. 
This included experiments at different levels involving 
commercial insurance companies, bilateral agencies, NGOs 
and state and national governments. These experiences 
have certainly generated a momentum for larger policylevel
efforts to mainstream HIV in the insurance sector. This paper 
presented assessment of managerial and coverage abilities 
of seven such experiments.
Cost recovery and sustainability are interrelated and 
important characteristics of any insurance scheme. Small 
and disease-specific pools are not sustainable and are dif-
ficult to upscale and replicate. Any disease-specific schemes 
are against the fundamental basis of insurance and results 
Figure 6: Three dimension of HIV coverage: comparison 
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have indicated the same for HIV-specific policies as well. 
An important finding points to the fact that a HIV-specific 
scheme is not the way forward.
Although HIV-specific policies offer tailor-made coverage, 
and provide opportunities for providing specified care 
through experts, these schemes suffer from issues of 
sustainability as they offer a limited risk and finance pooling. 
Most importantly, these schemes rely heavily on donor 
funding that is provided for administrative costs as well as 
subsidising the premium. Donor funding to demonstrate 
the possibility of health insurance coverage for HIV was 
essential; however, the findings indicate that this model is 
not sustainable on its own in the absence of such financial 
support.
HIV-sensitive schemes, on the other hand, promote 
mainstreaming and ensure pooling across various risks, 
but they largely exclude non-poor PLHIV. HIV-sensitive 
schemes are better off with larger and better pooling, and 
have enhanced avenues for cost recovery and sustainability 
in the presence of government subsidies. Such subsidies 
are not based on HIV infection status; they are available to 
economically weaker sections of society, irrespective of their 
disease status. This kind of provision of government subsidy 
promotes targeting public funds from an equity perspective 
as well. Thus, for the HIV positive population, there remains 
a trade-off between positive discrimination through getting
disease-specific insurance and becoming mainstreamed to 
avoid negative discrimination. [43]
Advocacy efforts are occurring in a few states to provide 
blanket inclusion of PLHIV in the BPL list so as to enable 
them to access all other social protections. [44] This is 
based on an argument that HIV households who were poor 
but not necessarily in possession of the BPL card could 
not access benefits of many social protection schemes 
that were targeted only to BPL households. However, 
awarding disease-based conditional BPL status cannot be 
an equitable solution, as the BPL status has to be based on 
economic criteria. HIV need not be treated differently than 
other chronic diseases. The ‘equity across diseases’ argument
in favour of covering HIV in existing health insurance 
mechanisms like other chronic diseases does not go 
hand-in-hand with the advocacy for awarding HIV-specific 
conditional BPL status to every PLHIV irrespective of their 
economic status.
The small-scale exclusive schemes have clearly initiated 
advocacy and attempted to fill the gaps in terms of data and 
experience in providing HIV coverage. The comprehensive 
government sponsored schemes offer potential for such 
coverage within their equity-based coverage ambit. The 
Insurance Regulatory and Development Authority (IRDA) 
issued an exposure draft in February 2012 to ‘provide 
insurance cover to persons living with HIV and people 
vulnerable to HIV/AIDS, under health insurance policies of 
both life and non-life insurance companies’. The National 
AIDS Control Organisation also constituted a working 
group on providing health insurance to PLHIV and those 
vulnerable to HIV in September 2012. In February 2013 
the IRDA was further directed by the Delhi High Court to 
act swiftly on the implementation of guidelines providing 
health insurance coverage for PLHIV. In 2013 the Institute 
of Actuaries in India released two important studies on 
mortality and morbidity among PLHIV, to fill the data gap 
in the insurance industry. Lastly, the Standing Committee 
on Health and Family Welfare of the Rajya Sabha recently 
submitted its report on the ‘Human Immunodeficiency Virus 
(HIV) and Acquired Immune Deficiency Syndrome (AIDS) 
(Prevention and Control) Bill, 2014’ on April 29, 2015. Among
other things, the Bill stated that ‘there should not be denial 
or unfair treatment in providing insurance cover to people 
living with HIV (PLHIV)’.
The findings of this research indicate that HIV-specific 
policies should be a preferred option. In order to improve 
mainstreaming, it is important that exclusions clauses in 
existing commercial health insurance products are removed. 
This will enable people – irrespective of their economic 
status – to purchase commercial health insurance, if they so
desire. Lastly, it is important to ensure that all PLHIV who are 
of poor economic status are made eligible so that they are 
able to purchase government-sponsored health insurance.
There remain challenges for stakeholders to take the various 
provisions forward and make them a reality in terms of 
adequate enrolment and utilisation of such schemes. The 
government needs to play an important stewardship role to 
ensure that provisions made within the existing insurance 
system do not remain as mere tokenism.
Limitations
While seven case studies were conducted, detailed data was 
available for only two cases. i.e. Freedom Foundation and 
Star Netplus scheme. This was largely because four of these
cases were government-sponsored schemes and it was 
difficult to get a complete set of data from any of them. 
Also, Karuna Trust scheme lacked documentation that 
was conducive to good research. Attempts were made to 
compile detailed data from all schemes but without any 
substantial success.
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